This is a news story, published by CNBC, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss medication Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest generic injection liraglutide news, weekly injections Zepbound news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weight loss medicationsCNBC
•Health
Health
83% Informative
Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro .
The company's GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
With Tuesday 's rally, Hims and Hers shares are up about 27% in 2025 after soaring 172% last year .
VR Score
79
Informative language
76
Neutral language
64
Article tone
formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
4
Affiliate links
no affiliate links
Small business owner?
